Zoledronic acid increases bone mineral density, reduces recurrence in postmenopausal

[News]

The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial.

More... (http://www.news-medical.net/news/20111208/Zoledronic-acid-increases-bone-mineral-density-reduces-recurrence-in-postmenopausal-breast-cancer.aspx)